Safehold enters the back half of August with a fresh analyst downgrade, a stock trading near multi-month lows, and options positioning that has shifted notably more defensive over the past month — a convergence of cautious signals that frames the week's setup.
The most immediate catalyst arrived on August 19, when Raymond James reinstated coverage with a Market Perform rating, stepping back from a prior Outperform stance. That move matters: it brings the consensus squarely into hold territory, with six analysts now lined up there and no visible upgrades on the recent tape. Goldman Sachs cut its target from $27 to $23 back in May, and RBC downgraded to Sector Perform around the same time, trimming its target to $16. Morgan Stanley carries an Underweight with a $14 target — effectively at current prices. The direction of travel across the Street has been uniformly lower, and the Raymond James reinstatement this week confirms that tone has not shifted. Goldman's $23 target implies meaningful upside from $14.80, but targets have been falling, not rising, and the stock has tracked that drift downward. The mean analyst target has been revised repeatedly to the downside, and the bear case — litigation on the Park Hotels portfolio, elevated long-term rates suppressing ground lease originations, and funding constraints — has gained more traction than the bull case.
Positioning in the lending market and options market tells a consistent story of limited conviction in either direction. Availability is extremely loose at 1,221%, meaning there are roughly twelve shares available to borrow for every one currently lent out — near the highest level of the past year. That is the opposite of a crowded short: borrow costs are low at just 0.52%, down roughly a quarter over the past month. Short interest has barely moved, sitting at 4.6% of the free float with less than 1% change on the week. The short score of 53.1 is mid-range and has been flat for two weeks. On the options side, the put/call ratio has climbed to 1.28, above its 20-day average of 1.18 — modestly defensive, but not extreme. What is notable is the structural shift in the PCR over the past month: readings were close to 1.0 through late July, and have moved consistently higher since early August, mirroring the stock's slide.
The stock's relative underperformance is stark against its REIT peers this week. CUBE was flat, EXR barely moved, and FCPT gained 1.5% on the week. SAFE dropped 3.3% — the weakest performance in the peer group — while declining 13.5% over the past month, a move that stands out even against a broader REIT sector that has been range-bound. Valuation offers little comfort: the stock trades at 0.43x book and a PE of 9.1x, both of which have compressed further over the past 30 days. The EV/EBITDA multiple has drifted to 16x, also lower over the month. Factor scores reinforce the caution — EPS momentum ranks in the 19th percentile over 30 days and the 22nd percentile over 90 days, pointing to consistent downward estimate drift. The dividend score at the 99th percentile reflects the income appeal, but the dividend history in the data is stale, and there is no current yield confirmation.
On the ownership side, the concentration is worth noting. Star Holdings holds just under 20% of shares. BlackRock added around 200,000 shares through July. T. Rowe Price added nearly 400,000 shares through June, and Columbia Management built a meaningful position of over 740,000 shares in the same period. These are steady, institutional accumulation moves — not aggressive repositioning — but they do suggest some large-cap managers are willing to hold at these levels rather than reduce. Insider activity, though now several months stale, showed the CEO and CFO both selling at higher prices earlier in the year, with no open-market buying on record.
The next earnings date is October 30. That print is unlikely to be about whether Safehold's ground lease model is working in the abstract; it will be about whether litigation overhangs on the Park Hotels portfolio have clarified, whether origination volumes have held up under rate pressure, and whether management can point to any tightening in funding conditions. The Raymond James reinstatement this week, with no price target attached, is itself a signal worth watching — when a firm reinstates without conviction on a number, the question of where the next analyst move lands becomes the clearest near-term tell.
See the live data behind this article on ORTEX.
Open SAFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
